Cell and gene therapies can radically change treatment
13 Jan 2021
Mariecar Jara-Puyod,
Senior Reporter
Cell and gene therapies combined with the burgeoning digital health and artificial intelligence shall remain to be a nucleus and continually pivot the intensely-competitive pharmaceutical industry, accelerating solutions for improved health and better outcomes.
This was emphasised at the “Virtual Pharma Media Day” of the healthcare-agriculture global enterprise Bayer on Wednesday (noon to 2.30 pm, UAE time), attended by 200 journalists from 30 countries. Cell therapy is the delivery or injection of “functioning cells into a patient’s body to achieve a medicinal effect-to prevent, manage or cure a certain illness or to repair and regenerate damaged cells.”
BRIEF—IND clearance for BlueRock s DA01 in Parkinson s disease
thepharmaletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepharmaletter.com Daily Mail and Mail on Sunday newspapers.
Dive Brief:
Bayer s venture investment arm is leading a $105 million funding round in closely held Senti Biosciences, a California-based company using synthetic biology to develop off-the-shelf cell therapies for cancer. It is at least the third cell therapy company to receive investment from Bayer, which has since acquired one of those companies.
Senti is advancing two experimental treatments using natural killer immune cells to attack tumors in leukemia and liver cancer. The company believes its technology can create treatments with greater precision and control than current cell therapies.
The investment is another sign that Bayer believes the future of cancer cell therapies is in off-the shelf, or allogeneic, approaches. Current cell therapies use patients own T cells to treat blood cancers, an approach that requires a lengthy manufacturing process in order to re-engineer the cells to attack diseased cells.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Cell Therapy Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell therapy market.
Major players in the cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., Kolon TissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure.
The global cell therapy market is expected to decline from $7.31 billion in 2019 to $7.2 billion in 2020 at a compound annual growth rate (CAGR) of -1.54%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupte
E-Mail
Skokie, IL - The ISSCR is bringing together successful biotech CEOs who have transformed scientific breakthroughs into thriving businesses that are improving human health into one program 7-8 January 2021.
VISION2030 comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect.
Thursday, 7 January
STEMCELL Technologies Executive Interview
Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA
STEMCELL Technologies mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools, and services that enable life science research.
Surrozen Executive Interview
Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder
vimarsana © 2020. All Rights Reserved.